MALIN CORPORATION PUBLIC LIMITED COMPANY

MALIN CORPORATION PUBLIC LIMITED COMPANY is a publicly listed investment group dedicated to backing cutting‑edge life‑science enterprises. By channeling long‑term capital and strategic support, Malin aims to generate strong shareholder returns while enabling its portfolio companies to bring transformative treatments to patients.

The firm’s investment focus centres on oncology, immunology and genetic diseases – areas where innovative therapeutics have the potential to reshape patient outcomes. Through close collaboration with its investee companies, Malin provides not only funding but also expertise that helps these businesses realise their full value, from early‑stage research through to commercialisation. Recent highlights include Mycovia Pharmaceuticals’ two‑year efficacy data for VIVJOA® and Poseida Therapeutics’ promising Phase 1 and pre‑clinical results presented at major scientific conferences.

With a clear purpose of marrying financial performance with real‑world health impact, Malin serves both the investment community and the patients who will ultimately benefit from the breakthrough therapies it helps to develop.